Sign In
Buy IOVA
$3.79
-0.310 (-7.56%)
At Close: Jun 03, 2026
Iovance Biotherapeutics: Buy, Because Short-Term Competitor Is Out
11:27am, Tuesday, 28'th Apr 2026
Iovance Biotherapeutics is rated a BUY following Replimune's exit, solidifying IOVA's lead in post-PD-1 melanoma. IOVA's lifileucel shows best-in-class ORR in earlier-line melanoma and promising effic
Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026
08:01am, Monday, 27'th Apr 2026
SAN CARLOS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor in
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
05:15pm, Friday, 17'th Apr 2026
SAN CARLOS, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and del
Is This Biotech Stock the Best Chance to Make a Fortune in Healthcare?
12:30pm, Friday, 10'th Apr 2026
Iovance Biotherapeutics' most important product is generating rapidly growing sales. Between approvals in other countries and label expansions, it could maintain its momentum for a while.
Iovance Biotherapeutics, Inc. $IOVA Shares Purchased by Aberdeen Group plc
03:08am, Friday, 10'th Apr 2026
Aberdeen Group plc raised its stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) by 25.1% during the undefined quarter, according to the company in its most recent 13F filing with the Sec
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Cross Below 50 Day Moving Average – Here’s What Happened
04:57am, Tuesday, 07'th Apr 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA - Get Free Report)'s share price passed below its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $3.42 and traded
Iovance Biotherapeutics: Positioned For Multi-Year Growth, Buy The Pullback
10:05pm, Monday, 06'th Apr 2026
Iovance Biotherapeutics is positioned for multi-year growth, with Amtagvi sales and pipeline momentum accelerating despite recent share price volatility. Real-world Amtagvi data shows a 44% ORR and 73
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Recommendation of “Hold” by Brokerages
02:27am, Saturday, 28'th Mar 2026
Shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA - Get Free Report) have been assigned an average recommendation of "Hold" from the twelve brokerages that are presently covering the firm, Marketb
Iovance Biotherapeutics (IOVA) Down 2.1% Since Last Earnings Report: Can It Rebound?
12:32pm, Thursday, 26'th Mar 2026
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock?
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
05:15pm, Friday, 20'th Mar 2026
SAN CARLOS, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and del
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments
03:25pm, Thursday, 12'th Mar 2026
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to surge to $366 billion in the next eight years. Companies often take a
Iovance Biotherapeutics, Inc. (IOVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
12:42pm, Wednesday, 11'th Mar 2026
Iovance Biotherapeutics, Inc. (IOVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
What's Going On With Iovance Biotherapeutics Stock On Friday?
01:06pm, Friday, 06'th Mar 2026
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) stock is trading higher on Friday, with no news to justify the movement.
Iovance Biotherapeutics (NASDAQ:IOVA) Hits New 52-Week High After Analyst Upgrade
01:52am, Friday, 06'th Mar 2026
Shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA - Get Free Report) reached a new 52-week high during trading on Thursday after UBS Group raised their price target on the stock from $2.00 to $4.0
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036
05:27pm, Thursday, 05'th Mar 2026
Iovance Biotherapeutics' most important product has strong momentum right now. However, the company faces significant challenges that make the stock risky.
